Deficiency in mTORC1-controlled C/EBPβ-mRNA translation improves metabolic health in mice by Zidek, L.M. et al.
Article
Deficiency in mTORC1-controlled C/EBPb-mRNA
translation improves metabolic health in mice
Laura M Zidek1, Tobias Ackermann2, Götz Hartleben1,2, Sabrina Eichwald1, Gertrud Kortman2,
Michael Kiehntopf3, Achim Leutz4, Nahum Sonenberg5, Zhao-Qi Wang1, Julia von Maltzahn1,
Christine Müller1,2,† & Cornelis F Calkhoven1,2,*,†
Abstract
The mammalian target of rapamycin complex 1 (mTORC1) is a
central regulator of physiological adaptations in response to
changes in nutrient supply. Major downstream targets of mTORC1
signalling are the mRNA translation regulators p70 ribosomal
protein S6 kinase 1 (S6K1p70) and the 4E-binding proteins (4E-BPs).
However, little is known about vertebrate mRNAs that are
specifically controlled by mTORC1 signalling and are engaged in
regulating mTORC1-associated physiology. Here, we show that
translation of the CCAAT/enhancer binding protein beta (C/EBPb)
mRNA into the C/EBPb-LIP isoform is suppressed in response to
mTORC1 inhibition either through pharmacological treatment or
through calorie restriction. Our data indicate that the function of
4E-BPs is required for suppression of LIP. Intriguingly, mice lacking
the cis-regulatory upstream open reading frame (uORF) in the
C/EBPb-mRNA, which is required for mTORC1-stimulated transla-
tion into C/EBPb-LIP, display an improved metabolic phenotype
with features also found under calorie restriction. Thus, our data
suggest that translational adjustment of C/EBPb-isoform expression
is one of the key processes that direct metabolic adaptation in
response to changes in mTORC1 activity.
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Introduction
C/EBPb is a transcriptional regulator with a broad tissue expression
including liver and adipose tissue (http://www.genecards.org). It
controls genes related to glucose and fat metabolism as well as other
cellular processes [1,2]. The Cebpb gene is intronless, and from its
mRNA three different protein isoforms are expressed through usage
of alternative translation initiation sites (Fig EV1A). The isoforms
LAP* and LAP (liver activating protein) are transcriptional activa-
tors that consist of transactivation domains and a DNA-binding
domain. The truncated isoform LIP (liver inhibitory protein) lacks
the N-terminal transactivation domains but still possesses the DNA-
binding domain. LIP can therefore act as a competitive inhibitor of
LAP*/LAP function [3]. However, LIP may also have additional and
distinct functions. Hence, the ratio between LAP and LIP is crucial
for the biological functions elicited by C/EBPb. Translation from
both the LAP* and LAP AUG codons is achieved by regular transla-
tion initiation, although translation into LAP* is often weaker since
this AUG codon lacks a Kozak consensus sequence required for effi-
cient recognition by the ribosome [4,5]. Expression of LIP from a
distal initiation codon depends on a cis-regulatory uORF located in
the 50 UTR of the C/EBPb-mRNA. The limited size of the uORF allows
the small ribosomal subunit to remain attached to the mRNA after
translation termination and to resume scanning along the mRNA.
After reloading of the ribosomal complex with initiator tRNA, transla-
tion of LIP from the downstream initiation codon can be re-initiated.
Mutation of the uORF consequently results in diminished LIP
expression [4,5] (see also schematic representation in Fig EV1A).
Reducing signalling through mTORC1 by pharmacological treat-
ment, mutations, restricted calorie intake or low protein:carbohy-
drate macronutrient ratio enhances metabolic health and increases
life span in many species up to mammals. On the contrary, hyper-
activation of mTORC1 is believed to promote metabolic disorders
resulting from overfeeding such as diabetes [6–15]. Our earlier
studies pointed to an involvement of mTORC1 signalling in the
regulation of C/EBPb-LIP expression, since mTORC1 inhibition by
rapamycin reduced LIP expression in a uORF-dependent manner
[4,16].
Here, we show that interventions that cause a reduction in
mTORC1 signalling also decrease the translation of the C/EBPb-LIP
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isoform. Genetic elimination of the mTORC1-sensitive uORF of
the C/EBPb-mRNA in mice similarly results in a reduction of the
LIP isoform [5]. Our data show that mice with this mutation
display an improved metabolic phenotype, including reduced
fat accumulation and increased b-oxidation, improved insulin
sensitivity and glucose tolerance as well as enhanced activity.
Thus, pharmacological targeting of C/EBPb-isoform expression
may provide a promising strategy for the treatment of metabolic
diseases such as obesity and type II diabetes, thereby extending
health span.
Results
mTORC1 controls C/EBPb-LIP expression
To clarify the regulation of C/EBPb-isoform expression by mTORC1,
we treated different cell lines with the catalytic pan-mTOR inhibitor
pp242 or the allosteric mTOR inhibitor rapamycin. Rapamycin
primarily acts on mTORC1 but was shown to also affect mTORC2
after prolonged treatment [17]. Treatment with pp242 resulted in a
strong reduction in LIP levels without affecting LAP expression in
all cell lines tested (Figs 1A and EV1B). pp242 treatment consis-
tently resulted in strong de-phosphorylation of the mTORC1 targets
S6K1 (Thr389) and 4E-BP1 (Thr37/46), which was analysed with
phospho-specific antibodies. Reduced phosphorylation of 4E-BP1 is
also visible in the pan-4E-BP1 immunoblots as a decrease in c/b-
phosphorylation signals and an increase in a-hypophosphorylation
signals. Treatment with rapamycin strongly reduced S6K1 phos-
phorylation in all cases. However, the effect on 4E-BP1 phosphory-
lation and LIP levels was weaker and varied between different cell
types (Figs 1A and EV1B). The correlation between 4E-BP1 phosp-
orylation state and LIP expression levels suggests that decreased
phosphorylation of 4E-BP1 and the resulting restrain of eukaryotic
initiation factor 4E (eIF4E) are important for reducing LIP expres-
sion through mTORC1 inhibition in these cells. To discriminate
between effects on C/EBPb-isoform expression by 4E-BPs or S6K1,
we used 4E-BP1/4E-BP2 double knockout (4E-BP DKO) MEFs
(mouse embryonic fibroblasts), or MEFs treated with either the
S6K1 inhibitor DG2 or an sh-RNA targeting S6K1. It has been shown
that 4E-BP DKO MEFs contain more accessible eIF4E [18,19]. In
4E-BP DKO cells, expression of LIP was strongly increased
compared to control cells. This was concomitant with a lower LAP/
LIP ratio, which could not be reversed by pp242 treatment (Fig 1B).
Treatment with the S6K1 inhibitor DG2 also did not reduce LIP
expression in wt MEFs, GH3 or 3T3-L1 cells although S6K1 activity
was completely abolished as shown by the lack of S6 (Ser235/236)
phosphorylation (Figs 1C and EV1C). On the contrary, LIP levels
were enhanced by DG2 treatment. Similarly, S6K1 knockdown did
not reduce but rather stimulated LIP expression (Fig EV1D) by a yet
to be identified mechanism. Therefore, our data indicate that
mTORC1 inhibition decreases LIP expression rather through 4E-BPs
than through S6K1. Since pp242 inhibits both mTORC1 and
mTORC2 [20], we employed a knockdown of either the mTORC1-
specific component raptor or the mTORC2-specific component rictor
to clarify their involvement in the regulation of LIP expression.
Knockdown of raptor resulted in decreased LIP expression (higher
LAP/LIP ratio) and a concomitant decrease in phosphorylation
of S6K1 and 4E-BP1, while knockdown of rictor reduced the
rictor-mTORC2-sensitive Ser473-Akt phosphorylation but did not
change the LAP/LIP ratio, although we observed reduced expression
levels of all protein isoforms (Fig 1D). These data demonstrate
that only mTORC1 specifically regulates the ratio of LAP/LIP
expression.
Limiting mTORC1 activity through inhibition by rapamycin or
caloric restriction inhibits C/EBPb-LIP expression in vivo
To verify mTORC1-dependent C/EBPb-isoform expression in vivo,
mice were injected intraperitoneally with rapamycin and analysed
for expression of C/EBPb on protein level. In liver (Fig 2A) and
epididymal white adipose tissue (eWAT) (Fig 2B), treatment with
rapamycin led to higher LAP/LIP ratios mainly resulting from
decreased LIP expression. The efficacy of mTORC1 inhibition
through treatment with rapamycin was shown by reduced phos-
phorylation of S6K1, S6 or 4E-BP1.
The mTORC1 signalling pathway is an important regulator of
metabolic adaptations in response to nutritional changes. Therefore,
we examined mTORC1-mediated C/EBPb regulation in adult wt
mice fed either ad libitum (AL) or caloric restricted (CR) for
4 weeks. As described by [21], mice on a CR regime consume their
daily single food allotment immediately followed by a prolonged
period of absence of food (mice fed AL spread their food intake
over the day). This results in a pronounced change in whole body
fuel selection with an initial nutrition phase of high carbohydrate
utilisation and a prolonged starvation phase of primarily fat utilisa-
tion that lasts until the next feeding [21]. We verified the dynamics
of fuel selection in AL and CR mice by calculating the respiratory
exchange ratio (RER) between the amount of CO2 exhaled and O2
inhaled from mice kept individually in metabolic chambers
(RER = VCO2/VO2 = 1.0 for pure carbohydrate usage; RER = 0.7
for pure fat usage) (see Fig EV2A and legend for further explana-
tion). This analysis allows covering these accentuated nutritional
states for analysing mTORC1 activity and C/EBPb-isoform expres-
sion. We chose 3 and 14 h after feeding as time points of analysis
since they represent the maximal usage of carbohydrate or fat in CR
fed mice, respectively. At 3 h post-feeding, mTORC1 activity was
slightly reduced in livers from CR compared to mice fed AL as
reflected by the levels of phosphorylated S6 and 4E-BP1 (Fig 2C).
This correlated with a moderate reduction in LIP levels and resulted
in a slight change in the LAP/LIP ratio in the CR fed mice.
However, in the starvation phase at 14 h, both mTORC1 activity
and LIP expression were reduced to a higher extent in the CR fed
mice compared to mice fed AL (Fig 2C). Mice fed AL display more
moderate diurnal cycles of fuel selection with a relative high
mTORC1 activity and a LAP/LIP ratio that stays constant at 3 and
14 h (Fig 2C). These data show that mTORC1 signalling alternates
between the activated and suppressed state in liver during the
diurnal cycle of fuel selection under CR. Furthermore, these
data demonstrate that LIP expression levels follow the changes
in mTORC1 activity also under these physiologically induced
conditions.
Taken together, our data show that expression of the C/EBPb-LIP
isoform correlates with mTORC1/4E-BP1 signalling in vitro and
in vivo and follows mTORC1 activity upon changes in calorie supply
or pharmacological inhibition of mTORC1.
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Permanent reduction of C/EBPb-LIP expression in C/EBPbDuORF/BL6
mice enhances fat metabolism
To investigate whether a permanently altered C/EBPb-isoform
ratio affects metabolic performance, we analysed mice deficient in
the cis-regulatory uORF that is required for LIP expression
(C/EBPbDuORF/BL6 mice; based on mice described in [5], but
back-crossed in C57BL/6J background, see also Fig EV1A). These
mice display a diminished LIP expression that was not further
reduced by rapamycin treatment (Figs 2D and EV2B) or through
caloric restriction (Fig 2E). Thus, the C/EBPbDuORF/BL6 mice with
their invariably low LIP expression mimic reduced mTORC1 activity
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Figure 1. Regulation of LAP/LIP C/EBPb-isoform expression through the mTORC1 signalling pathway.
A Immunoblots of extracts from MEFs treated with the pan-mTOR inhibitor pp242 (1 lM) or the allosteric mTORC1 inhibitor rapamycin (1 lM) compared to solvent
(DMSO) for 12 h showing phosphorylation (p-) in relation to total levels of the indicated proteins. Upper bar graph shows quantification of percentages of 4E-BP1
a- (hypophosphorylated), b- and c-bands (hyperphosphorylated) of the pan-4E-BP1 blot shown. The lower bar graphs show quantification of the relative changes in
LAP/LIP-isoform ratio by pp242 or rapamycin compared to solvent (n = 4 independent experiments).
B Immunoblots of extracts from wt and 4E-BP DKO MEFs treated with pp242 (1 lM) or solvent (DMSO) for 12 h showing phosphorylation (p-) in relation to total
protein levels as indicated. The bar graph shows quantification of the relative change in LAP/LIP-isoform ratio by pp242 compared to solvent (n = 4, independent
experiments).
C Immunoblots of extracts from MEFs treated with the S6K1 inhibitor DG2 (20 lM) or solvent (DMSO) for 12 h. Phosphorylation (p-) in relation to total protein levels of
indicated proteins is shown. The bar graph shows quantification of the relative change in LAP/LIP-isoform ratio by DG2 compared to solvent (n = 4, independent
experiments).
D Immunoblots of extracts from MEFs with sh-RNA-mediated knockdown of raptor, rictor or control with detection of the indicated proteins and their phosphorylation
(p-). The bar graph shows quantification of the relative changes in LAP/LIP-isoform ratio (n = 1).
Data information: LAP/LIP C/EBPb-isoform ratios were quantified by chemiluminescence digital imaging or using ImageJ software from film scans. All values are
mean  SEM. P-values were determined with Student’s t-test, *P < 0.05; ***P < 0.005. b-actin was used as a loading control.
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at the level of C/EBPb translation. mTORC1 activity itself does not
seem to be influenced by the C/EBPbDuORF/BL6 mutation or the
reduced LIP levels since neither S6 phosphorylation nor 4E-BP1
phosphorylation was noticeably altered in livers from C/EBPbDuORF/BL6
mice compared to wt mice (3 h post-feeding) (Fig EV2C).
We found that C/EBPbDuORF/BL6 mice fed AL displayed a
reduced body weight compared to wt mice accumulating to a
difference of 8% at 26 weeks of age (Fig 3A). This was not due
to changes in body length, food intake or caloric utilisation
(Fig 3B–D). C/EBPbDuORF/BL6 mice even showed a slightly increased
food intake. To investigate why the body weight was reduced, we
performed an abdominal computed tomography (CT) to analyse
body composition. The data demonstrated that both visceral and
subcutaneous fat volumes were clearly reduced in C/EBPbDuORF/BL6
mice compared to age- and sex-matched littermate controls
(Fig 3E), while there was no significant change in the lean
body mass (Fig 3F). Histological analyses of epididymal fat pads
revealed an average reduction of white adipocyte cell size of 30% in
C/EBPbDuORF/BL6 male mice compared to wt control tissue (Fig 3G).
C/EBPb is a known regulator of adipogenesis and induces transcrip-
tion of the adipogenic transcription factors C/EBPa and PPARc.
mRNA expression levels of C/EBPa and PPARc were similar in
visceral adipose tissue of C/EBPbDuORF/BL6 mice compared to control
littermates. This indicates that the reduced fat accumulation in WAT
is not caused by deficiencies of key adipogenic transcription factors
(Fig EV3A). Notably, MEFs derived from C/EBPbDuORF/BL6 mice
displayed increased differentiation into adipocytes in cell culture
compared to MEFs derived from wt mice, as was revealed by Oil Red
O staining of lipid droplets (Fig EV3B). Vice versa, experimental
induction of LIP in 3T3-L1 adipocytes resulted in less efficient adipo-
genic differentiation and a reduction in fat accumulation (Fig EV3C)
reminiscent of what has been described before [4]. In accordance
with the lower fat content of C/EBPbDuORF/BL6 adipocytes, adiponec-
tin levels were increased (Fig 3H), while leptin levels were
unchanged (Fig EV3D) in the blood plasma of C/EBPbDuORF/BL6 mice
compared to wt controls. High levels of the adipocyte-derived
hormone adiponectin correlate with increased fatty acid oxidation,
reduced lipid accumulation in non-adipose tissues and increased
insulin sensitivity [22–24]. This prompted us to examine whether
whole body fatty acid oxidation is increased in the C/EBPbDuORF/BL6
mice by determination of the RER using metabolic cages. The RER
curves of both C/EBPbDuORF/BL6 and wt mice fed ad libitum reflected
the diurnal rhythm with a higher RER in the active (dark) phase
representing mostly carbohydrate usage and a lower RER in the rest-
ing (light) phase in which more fatty acids are oxidised. As shown in
Fig 4A, we measured continuously lower RER values both over the
active and over the resting phases for C/EBPbDuORF/BL6 mice
compared to wt mice. Thus, C/EBPbDuORF/BL6 mice have a moderate
but significant daily increase in fatty acid oxidation over carbohy-
drate oxidation under normal feeding conditions. Furthermore,
oxygen consumption of the C/EBPbDuORF/BL6 mice was increased
compared to wt mice, indicating that the C/EBPbDuORF/BL6 mice have
a higher energy expenditure (Fig 4B). To examine whether altering
the LAP/LIP ratio results in a cell intrinsic shift in b-oxidation, we
ectopically expressed LIP in the mouse hepatoma cell line Hepa 1-6
and studied palmitate-substrate fatty acid oxidation (FAO) using the
Seahorse FX extracellular flux analyser. Ectopic expression of LIP
(low LAP/LIP ratio) resulted in a reduced FAO compared to FAO in
the parent cells (high LAP/LIP ratio) (Fig 4C). Hence, the LAP-/LIP-
associated b-oxidation changes found in cell culture support the
phenotype found in C/EBPbDuORF/BL6 mice.
Increased fatty acid oxidation is known to improve the health
status by lowering the concentration of free fatty acids in the serum
and counteracting lipid accumulation in non-adipose tissues [25]. In
the serum of C/EBPbDuORF/BL6 mice, the concentration of free fatty
acids (FFA) and triglycerides (TG) was reduced compared to wt
mice, while the levels of cholesterol/high-density lipoprotein
(HDL)/low-density lipoprotein (LDL) were similar (Fig 4D). Further-
more, lipid accumulation in liver and heart was strongly reduced in
8-month-old C/EBPbDuORF/BL6 mice compared to wt littermates as
revealed by Sudan III staining (Fig 4E).
C/EBPbDuORF/BL6 mice display a CR-like metabolic gene
expression profile
Next, we analysed mRNA expression of genes involved in fat
metabolism that could be involved in the metabolic phenotype of
C/EBPbDuORF/BL6 mice. We measured a moderate but consistent shift
Figure 2. The LAP/LIP C/EBPb-isoform ratio in vivo is regulated by rapamycin or CR and is uORF dependent.
A Immunoblots of extracts from livers of fed wt mice 24 h after i.p. injection of rapamycin (8 lg/g body weight) or solvent. Phosphorylation (p-) in relation to total
protein levels of indicated proteins is shown. a-tubulin was used as a loading control. The upper bar graph shows quantification of percentages of 4E-BP1
a- (hypophosphorylated), b- and c-bands (hyperphosphorylated) of the pan-4E-BP1 blot, and the lower bar graph shows quantification of the LAP/LIP-isoform ratio
(n = 3).
B Immunoblots of extracts from epididymal (e)WAT of fed wt mice 12 h after i.p. injection of rapamycin (8 lg/g) or solvent showing phosphorylation (p-) of proteins in
relation to total levels. a-tubulin was used as a loading control. The upper bar graph shows quantification of percentages of 4E-BP1 a- (hypophosphorylated), b- and
c-bands (hyperphosphorylated) of the pan-4E-BP1 blot, and the lower bar graph shows quantification of the LAP/LIP-isoform ratio (n = 2).
C Immunoblots of extracts from of wt mice either fed ad libitum (AL) or under caloric restriction (CR) for 4 weeks and sacrificed either 3 or 14 h past-feeding.
Phosphorylation (p-) in relation to total protein levels of indicated proteins is shown. b-actin was used as a loading control. The bar graph shows quantification of
LAP/LIP-isoform ratio (n = 3).
D Immunoblots of extracts from liver of fed C/EBPbDuORF/BL6 mice 24 h after rapamycin (8 lg/g) or solvent injection (i.p.). Phosphorylation (p-) in relation to total levels
of indicated proteins is shown. a-tubulin was used as a loading control. The upper bar graph shows percentages of 4E-BP1 a- (hypophosphorylated), b- and c-bands
(hyperphosphorylated) of the pan-4E-BP1 blot, and the lower bar graph shows quantification of the LAP/LIP-isoform ratio (n = 3).
E Immunoblots of extracts from of C/EBPbDuORF/BL6 mice either fed ad libitum (AL) or under caloric restriction (CR) for 4 weeks and sacrificed either 3 or 14 h past-
feeding. The phosphorylation (p-) in relation to total protein levels is shown. b-actin was used as a loading control. The bar graph shows quantification of LAP/LIP-
isoform ratio (n = 3).
Data information: Quantification of the C/EBPb LAP/LIP-isoform ratio of the blots was done by chemiluminescence digital imaging for the CR experiment or from X-ray
films for rapamycin and is shown as bar graphs. All values are mean  SEM. P-values were determined with Student’s t-test, *P < 0.05; **P < 0.01.
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towards higher transcript levels of genes that are involved
in glucose/fat transport, lipogenesis and lipolysis in WAT of
C/EBPbDuORF/BL6 mice compared to littermate controls using quanti-
tative real-time PCR (Fig 5A). This points towards an increased fat
turnover in adipose tissue. We found elevated transcript levels of
the insulin-dependent glucose transporter GLUT4 (1.6-fold,
P = 0.027) required for glucose uptake for de novo lipogenesis.
Furthermore, we detected increased mRNA levels of fatty acid
translocase (FAT)/cluster of differentiation 36 (CD36) (1.5-fold,
P = 0.007) that is involved in fatty acid uptake. We observed a small
but not significant increase for lipoprotein lipase (LPL) (1.4-fold,
P = 0.052) or the intracellular fatty acid binding protein aP2
(1.2-fold, P = 0.376). In addition, transcripts that stimulate lipogene-
sis were elevated: the sterol regulatory element-binding protein 1c
(SREBP1c) (1.5-fold, P = 0.002), acetyl-CoA carboxylase (ACC),
which is the flux-determining enzyme of the lipogenic pathway
(1.4-fold, P = 0.021), the key enzyme in fatty acid synthesis fatty
acid synthase (FAS) (1.7-fold, P = 0.002) and stearoyl-coenzyme A
desaturase 1 (SCD1) (1.6-fold, P = 0.015), which is important for
the synthesis and regulation of unsaturated fatty acids. Finally,
among the transcripts that stimulate lipolysis, the hormone-
sensitive lipase (HSL) mRNA was elevated (1.4-fold, P = 0.007),
while upregulation of the adipose triglyceride lipase (ATGL)
transcript was not significant (1.3-fold, P = 0.142). Immunoblot
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analyses showed that the moderate increases in mRNA levels
correlate with significantly increased protein levels for FAS, ACC
and GLUT4. Smaller increases were observed for CD36 or HSL
(Fig EV4A). To investigate whether expression of genes involved in
b-oxidation is altered in WAT, we examined mRNA expression of
the short-chain (SCAD), medium-chain (MCAD), long-chain
(LCAD) and very long-chain (VLCAD) acyl-CoA dehydrogenases
(Fig 5A). Although we observed a general tendency towards
enhanced expression, only the MCAD transcript was found to be
significantly upregulated (1.7-fold, P = 0.013), which is also
reflected on the protein levels (Fig EV4A).
Next, we studied cell intrinsic effects of LAP/LIP ratio on
adipogenic gene expression in primary MEFs or the adipoblast
cell line 3T3-L1 in cell culture. Briefly, we transduced confluent
C/EBPbDuORF/BL6 MEFs with a lentivirus expressing either
C/EBPb-LIP or an empty control vector, and induced the adipo-
genic programme. mRNA expression of all examined adipogenic
genes was generally downregulated by ectopic expression of LIP
(low LAP/LIP ratio) compared to control C/EBPbDuORF/BL6 MEFs
(high LAP/LIP ratio) (Fig EV4B). In 3T3-L1 cells containing an
inducible LIP expression cassette (cumate-inducible system),
adipogenesis was induced simultaneously with LIP induction
(+ cumate) or without ectopic LIP induction ( cumate, solvent
treatment) as control. Induction of LIP resulted in reduced
expression of adipogenic transcripts measured at day 6 of differ-
entiation (Fig EV4C). Cumate treatment of the empty vector
control cells had no or a rather stimulatory effect on the expres-
sion of adipogenic genes, ruling out that cumate itself acts
anti-adipogenic. Therefore, LAP-/LIP-associated regulation of
adipogenic transcripts found in cell culture supports the observa-
tions we made in mice.
In the liver of C/EBPbDuORF/BL6 mice, the expression of the
following transcripts involved in fatty acid b-oxidation was upregu-
lated compared to wt mice: the peroxisome acyl coenzyme
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A oxidase (AOX) (1.6-fold, P = 0.007), SCAD (1.3-fold, P = 0.016),
MCAD (1.4-fold, P = 0.003), LCAD (1.3-fold, P = 0.009) and
VLCAD (1.3-fold, P = 0.009). Only expression of the FAT/CD36
mRNA for fatty acid uptake was not significantly increased
(1.7-fold, P = 0.057) (Fig 5B). On the contrary, transcript levels of
factors fostering lipogenesis were unchanged (GLUT2, SREBP1c,
ACC and SCD1) or even decreased (FAS, P = 0.041). Furthermore,
immunoblot analyses showed that expression of FAS and ACC
proteins (lipogenesis) is decreased, while expression of the MCAD,
AOX and CD36 (b-oxidation) was not significantly different
(Fig EV4D). To further support the direct regulatory role of C/EBPb
in the examined gene regulation, we analysed the ENCODE data-
base (http://genome.ucsc.edu/ENCODE/) for promoter occupation
by chromatin immunoprecipitation sequencing (ChIP-Seq). This
analysis revealed that all genes analysed are associated with
C/EBPb at regions that are in most cases associated with the
histone H3 lysine 27 acetylation (H3K27Ac) mark characterising
active enhancers (Table EV1).
C/EBPbDuORF/BL6 mice are physically more active
An intriguing aspect of the C/EBPbDuORF/BL6 phenotype is the lower
body weight in spite of similar food intake and caloric utilisation. This
points to an increased energy expenditure in C/EBPbDuORF/BL6 mice,
which is supported by the observed increase in oxygen consumption.
Possible causes for higher energy use are respiratory uncoupling in
BAT, browning of WAT or an increase in physical activity. To
examine the potential involvement of altered BAT or WAT function,
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Figure 5. Gene expression and physical activity changes in C/EBPbDuORF/BL6 mice.
A mRNA levels of depicted genes measured in epididymal WAT of C/EBPbDuORF/BL6 mice relative to wt mice (wt, n = 5; C/EBPbDuORF/BL6, n = 6).
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we analysed mRNA expression levels of genes involved in uncoupling
and thermogenesis (UCP1, PGC-1a, Dio2, PRDM16) in BAT, inguinal
(i) WAT or epididymal (e) WAT (Fig 5C). The expression of
those genes was very low in both iWAT and eWAT and not increased
in C/EBPbDuORF/BL6 mice excluding a critical involvement of
uncoupling or browning of WAT as a cause of the higher energy
expenditure.
To examine if an increase in physical activity could be the
cause for this phenotype, we determined physical activity of
C/EBPbDuORF/BL6 mice compared to age- and sex-matched littermate
controls using the Oxymax/CLAMS animal motion detection
system. As shown in Fig 5D, the total activity (Xtot; total counts of
fine movements (e.g. grooming) and ambulatory activity), as well
as the ambulatory activity (Xamb; “distance”) and vertical activity
(Ztot; “rearing”) of the C/EBPbDuORF/BL6 mice, were higher
compared to wt mice during their active period at night. Thus, the
reduced body weight of the C/EBPbDuORF/BL6 mice might be caused
by higher energy expenditure due to their increased physical
activity.
C/EBPbDuORF/BL6 mice have improved glucose clearance and
insulin sensitivity
Fat metabolism is highly interconnected with glucose metabo-
lism and particularly with insulin responsiveness. Therefore, we
analysed glucose metabolism in C/EBPbDuORF/BL6 mice. The intra-
peritoneal (i.p.) glucose tolerance test (IPGTT) revealed an
enhanced glucose clearance in C/EBPbDuORF/BL6 mice, which is
reflected by a smaller area under the curve (AUC) (Fig 6A). The i.p.
insulin sensitivity test (IPIST) demonstrated that C/EBPbDuORF/BL6
mice also display an increase in insulin sensitivity compared to wt
control mice (Fig 6B). Accordingly, tissue insulin sensitivity was
higher in C/EBPbDuORF/BL6 mice, as revealed by enhanced induction
of Akt-Ser473 phosphorylation in muscle and liver after intravenous
(i.v.) insulin injection (Figs 6C and EV5A). Improved insulin sensi-
tivity is usually accompanied by reduced levels of circulating
glucose and insulin, which is also found under caloric restriction
[26]. In C/EBPbDuORF/BL6 mice, fasting insulin and fed glucose levels
were lower compared to wt mice, while fasting glucose and fed
insulin levels showed no significant reduction (Fig 6D and E). The
significantly lower HOMA-IR (homeostatic model assessment of
insulin resistance) supports the conclusion that C/EBPbDuORF/BL6
mice show improvements in insulin sensitivity (Fig 6F). To
exclude that the lower insulin levels were due to aberrantly
reduced pancreatic b-cell mass, insulin production in the pancreas
was examined by quantitative immunofluorescence analysis. We
observed no difference in b-cell mass but a decreased insulin
production in C/EBPbDuORF/BL6 mice compared to wt mice
(Fig EV5B). This indicates that the improved tissue insulin sensi-
tivity in C/EBPbDuORF/BL6 mice requires less insulin production for
efficient function.
Discussion
Reduced mTORC1 signalling is thought to be responsible for many
of the metabolic improvements under caloric restriction (CR) [7]
and is believed to attenuate the development of the metabolic
syndrome [15]. Here, we show that the C/EBPbDuORF/BL6 mice
display a range of metabolic improvements that are remarkably
similar to what has been described for CR, however, without reduc-
ing calorie (food) intake. Loss of the C/EBPb uORF leads to dimin-
ished expression of the C/EBPb-LIP isoform in vitro and in vivo
[4,5]. This mimics reduced mTORC1 activity at the level of C/EBPb
translation and is sufficient to improve a whole set of metabolic
health parameters.
We observed a gradual difference in body weight for the
C/EBPbDuORF/BL6 mice compared to wt mice, which becomes
apparent after maturity (week 12) and accumulates to a reduction of
8% in adult C/EBPbDuORF/BL6 mice (week 26) (Fig 3A). The reduced
body weight of the C/EBPbDuORF/BL6 mice is largely due to reduced
fat accumulation in WAT. This is accompanied by increased levels
of the adipocyte-specific hormone adiponectin and a metabolic shift
in whole body energy utilisation towards more fatty acid oxidation
(lower RER) (Figs 3E and H, 4A). In addition, we found increased
expression of lipogenesis and lipolysis genes in WAT and increased
expression of b-oxidation genes in liver (Fig 5A and B). Together
with the enhanced adipocyte differentiation of C/EBPbDuORF/BL6
MEFs (Fig EV3B) in cell culture, the increased expression of
lipogenesis genes in WAT may seem to be inconsistent with the
lower fat accumulation and leanness in the C/EBPbDuORF/BL6 mice.
However, increased expression of lipogenesis and lipolysis genes in
WAT and increased expression of b-oxidation genes in liver are also
observed in mice on CR [21,27–30]. Intriguingly, in calorie-restricted
mice, fatty acid oxidation exceeds fat intake [21]. Thus, additionally
required amounts of fat are generated from ingested carbohydrates
by de novo lipogenesis in WAT followed by lipolysis to meet the
increased requirements of fatty acids for energy production. The
C/EBPbDuORF/BL6 mutation may induce a similar metabolic round-
about of enhanced WAT function and fat turnover coupled to
increased fatty acid oxidation.
The number of fat cells in WAT of the C/EBPbDuORF/BL6 mice,
as can be calculated from the fat volume (CT analysis) and cell
size (histology), does not seem to be altered, indicating that
the reduction of fat mass observed in C/EBPbDuORF/BL6 mice
results from less fat storage. This suggests that the enhanced
adipogenic differentiation potential observed in MEFs derived
from C/EBPbDuORF/BL6 mice in vitro does not lead to increased
number of adipocytes in vivo.
The prolonged period of increased fatty acid oxidation is thought
to contribute to the healthy phenotype induced by CR [21]. This is
also supported by a study in flies, which shows that the reduction in
fatty acid oxidation limits CR-induced life span extension [31].
Therefore, we hypothesise that C/EBPb is an important factor in
regulating the CR type of fat metabolism. Moreover, we postulate
that the increased LAP/LIP ratio as a result of the DuORF mutation
retains this metabolic state in C/EBPbDuORF/BL6 mice without
reduction in food intake. A high rate of fatty acid oxidation
prevents the accumulation of lipids in the liver and in other non-
adipose organs [25]. Reduction in liver fat has been shown to
increase insulin sensitivity [32]. We found decreased levels of free
fatty acids in the serum and strongly reduced lipid accumulation
in liver and heart of C/EBPbDuORF/BL6 mice compared to wt litter-
mates. Moreover, we found lower glucose and insulin levels in the
serum with concomitantly increased glucose tolerance and insulin
sensitivity [29]. Together with the increased fatty acid oxidation,
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these findings underscore the healthy metabolic condition of the
mice.
The C/EBPbDuORF/BL6 mice have a similar food intake compared
to wt mice but are leaner most probably due to higher energy expen-
diture as indicated by their increased oxygen consumption. An
important question deals with the underlying cause of the higher
energy expenditure. Our data indicate that neither increased respira-
tory uncoupling in BAT nor browning of WAT are causative factors
for the higher energy expenditure. However, the C/EBPbDuORF/BL6
mice display an increased physical activity, suggesting that the
associated higher energy expenditure contributes to the lower body
weight (Fig 5D). Elevated physical activity is also associated with
rapamycin treatment [33,34] or CR [35–37]. This suggests that the
C/EBPbDuORF/BL6 mutation might mimic effects of mTORC1 inhibi-
tion on physical activity. Intriguingly, a study using flies demon-
strated that increased activity is not only associated with CR but is
also at least partially required to induce the beneficial effects of
CR [31].
The transcriptional effects we observed in the C/EBPbDuORF/BL6
mice are moderate (Fig 5A and B), although they translate into
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changes on protein levels in most cases. The more subtle changes in
gene expression may support the improved overall metabolic
phenotype: a small and consistent shift in gene regulation resulting
in a continuous shift in metabolism as suggested by the continu-
ously lower RER (Fig 4A) that is still in a physiological range. Stron-
ger transcriptional effects may result in a fully unbalanced
metabolism with detrimental metabolic effects. In addition to its
direct involvement in gene regulation, the C/EBPbDuORF/BL6 muta-
tion most likely results in systemic (hormonal) alterations such as
increased serum concentration of adiponectin that contributes to the
improved metabolic parameters.
The phenotypes observed in C/EBPbDuORF/BL6 mice are similar to
those described for C/EBPb/ complete knockout mice with diet-
or genetically induced obesity. C/EBPb/ mice on a high fat diet
display a reduced accumulation of body fat, are resistant to steatosis
and have enhanced fatty acid oxidation compared to wt mice that
develop an obese phenotype [38]. Leprdb/db mice are homozygous
for a loss of function mutation in the Leptin receptor and become
obese at ~4 weeks of age. Complete C/EBPb deficiency in Leprdb/db
mice results in a general healthier metabolic phenotype with
reduced total body fat and weight gain, less steatosis, enhanced fatty
acid oxidation and better glucose homeostasis [39]. The fact that the
metabolic phenotype of C/EBPbDuORF/BL6 mice (normal expression
levels of LAP) resembles the one of C/EBPb/ knockout mice
suggests that the lack of the LIP isoform and nor the lack of LAP is
decisive for the phenotype. Therefore, the complete C/EBPb knock-
out may display the beneficial metabolic phenotypes because of its
deficiency for the metabolic “harmful” LIP isoform that is under
control of mTORC1.
Many open questions remain how CR and the associated meta-
bolic changes influence health span. However, it is intriguing that
mutation of a single mRNA-translation cis-regulatory element in a
single gene results in a phenotype that (at least partially) resembles
the phenotype induced by CR. This implies that pharmacological
alteration of the C/EBPb-isoform ratio may provide a promising
therapeutic strategy to intervene with metabolism-related disorders,
thereby increasing health span.
Materials and Methods
Cell culture
HEK293T, Fao, 3T3-L1 (all obtained from ATCC), Hepa 1-6 cells, p53/
MEFs, 4E-BP wt and DKO MEFs [19], immortalised C/EBPbDuORF/BL6
and C/EBPb KO MEFs and freshly isolated C/EBPbDuORF/BL6 and
C/EBPb KO MEFs and the corresponding wt MEFs were maintained
in DMEM supplemented with 10% FCS, 1% HEPES and penicillin/
streptomycin. GH3 cells were maintained in F12K medium supple-
mented with 15% horse serum, 2.5% FCS, 1% HEPES and penicil-
lin/streptomycin. For mTOR repression, cells were incubated with
pp242 (1 lM) or rapamycin (1 lM or 200 nM for GH3 cells) for
different time periods (6 h for Fao, 12 h for MEFs, 24 h for 3T3-L1
and GH3). For S6K1 inhibition, cells were incubated with DG2
(20 lM) for different time periods (12 h for MEFs, 24 h for 3T3-L1
and GH3). For inhibitor treatment, 3T3-L1 cells had been differenti-
ated for 4 days (as described for primary MEFs but in the absence of
troglitazone).
DNA constructs
The mouse S6 kinase 1 shRNA expression vector was generated by
annealing the oligonucleotides sh-a 50-CCG GAC ATT GTT ACA
CAG CCA GTA TCT CGA GAT ACT GGC TGT GTA ACA ATG TTT
TTT-30 and sh-b 50AAT TAA AAA ACA TTG TTA CAC AGC CAG
TAT CTC GAG ATA CTG GCT GTG TAA CAA TGT-30 and ligating
them into the Tet-pLKO-puro vector (Addgene plasmid 21915,
described in [40]). For generating the C/EBPb-LAP or C/EBPb-LIP
expression vectors, the rat C/EBPb mutants DD and C, respectively,
that are described in [4] were cloned into pCDNA3 or pZeoSV2
vector (both from Invitrogen). A FLAG-tagged version of rat
C/EBPb-LIP [16] was cloned into the lentiviral pLVX-IRES-neo
expression vector (Clontech), and for the generation of the cumate-
inducible C/EBPb-LIP-FLAG lentiviral construct, it was cloned into
the pCDH-CuO-MCS-IRES-GFP-EF1-CymR-T2A-Puro-All-in-one vector
(System Biosciences).
Isolation and differentiation of primary MEFs
Mouse embryonic fibroblasts (MEFs) were isolated from embryos
at embryonic day 14.5 following standard protocols. Cells from
passage 3 were seeded into 10-cm dishes for differentiation assays.
Adipogenic differentiation was induced 2 days after cells reached
confluency by replacing the medium with differentiation medium
(DMEM containing 1 lM dexamethasone, 0.5 mM methylisobu-
thylxanthine, 10 lg/ml insulin, 10 lM troglitazone and 10% FCS).
After 2 days of incubation, the medium was replaced by DMEM
supplemented with 10 lg/ml insulin and 10% FCS and then
replaced every second day. At different days of the differentiation
protocol, cells were fixed with 4% PFA and stained with Oil Red
O.
Immortalisation of primary MEFs
Primary MEFs of passage 2 were retrovirally infected with a
pSUPER-retro-based shRNA construct targeting p19ARF using the
PhoenixE producer cell line as described in [4] and selected with
puromycin (1.5 lg/ml).
Transfection
For lentivirus production, HEK293T cells were seeded to a density
of 3 × 106 cells in 10-cm culture dishes. Twenty-four hours later,
transfection was carried out using the calcium phosphate method.
For stable C/EBPb-LIP expression, a pCDNA3-based LIP expression
vector was transfected into Hepa 1-6 cells using the Fugene HD
transfection reagent (Promega) according to the protocol of the
manufacturer. Transfected cells were selected with 0.9 mg/ml
G418. For stable expression of C/EBPb-LAP*, C/EBPb-LAP and
C/EBPb-LIP immortalised C/EBPb KO MEFs were transfected with
pZeoSV2-based expression vectors using the Fugene transfection
reagent and selected with zeocin (0.1 mg/ml).
Lentiviral transduction
p53/ MEFs were infected following a standard protocol with
pLKO.1 lentiviral constructs containing shRNAs against mouse
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raptor: sh 50-CCG GCC TCA TCG TCA AGT CCT TCA ACT CGA GTT
GAA GGA CTT GAC GAT GAG GTT TTT G-30 (Addgene plasmid
21339); mouse rictor: 50- CCG GGC CAG TAA GAT GGG AAT CAT
TCT CGA GAA TGA TTC CCA TCT TAC TGG CTT TTT G-30 (Add-
gene plasmid 21341), both described in [41], mouse S6 kinase 1: 50-
CCG GAC ATT GTT ACA CAG CCA GTA TCT CGA GAT ACT GGC
TGT GTA ACA ATG TTT TTT-30 or non-target shRNA control
(Sigma-Aldrich). Two days after infection, puromycin was added
(final concentration 1.5 lg/ml). Cells were harvested for analysis
4 days after infection. Due to leakiness of the inducible S6 kinase-
shRNA Tet-pLKO-puro construct, cells treated with doxycycline
(100 ng/ml, 48 h) were compared with doxycycline-treated control
shRNA-expressing cells. One day before induction of adipogenic
differentiation, confluent plates of primary MEFs were infected with
a pLVX-IRES-neo-based C/EBPb-LIP-FLAG construct. Forty-eight
hours after infection, G418 was added (0.4 mg/ml), which was
replenished upon every medium change. 3T3L1 cells were infected
with a cumate-inducible C/EBPb-LIP-FLAG construct or an empty
vector construct and selected with puromycin (1.5 lg/ml). Cells
from an individual clone that showed good inducibility were
differentiated as described for primary MEFs but in the absence of
troglitazone. During the whole differentiation period, puromycin
was added in a concentration of 1 lg/ml and cells were treated with
cumate (12 lg/ml) or solvent (ethanol) starting at day 0 of the
differentiation protocol.
Fatty acid oxidation assay
Fatty acid oxidation was determined using a Seahorse XF96 Extra-
cellular Flux analyser (Seahorse Bioscience). 2 × 104 Hepa 1-6 cells
per well were seeded into a 96-well XF cell culture microplate 24 h
prior to the assay. Sixteen hours before the assay, cells were washed
and the medium was replaced with DMEM containing 0.5 mM
glucose, 1 mM glutamine, 0.5 mM carnitine and 1% FCS to deplete
the cells from oxidation substrates. One hour before the assay, the
cells were washed twice with FAO assay buffer (111 mM NaCl,
4.7 mM KCl, 1.25 mM CaCl2, 2.2 mM MgSO4, 1.2 mM NaH2PO4,
2.5 mM glucose, 0.5 mM carnitine, 5 mM HEPES, pH 7.4), and
15 min before the assay, the oxidation substrate palmitate-BSA or a
BSA control (Seahorse Bioscience) was added and the oxygen
consumption rate (OCR) with or without palmitate-BSA was
measured.
Mice
C/EBPbDuORF mice [5] were back-crossed for 6 generations into the
C57BL/6 genetic background (C/EBPbDuORF/BL6). Male mice that
were kept at a standard 12-h light/dark cycle at 22°C in a pathogen-
free animal facility were used for all experiments. Numbers of mice
used in the separate experiments can be retrieved from the figure
legends. Body weight and food consumption (standard chow) were
measured weekly for 26 weeks. Body length was determined from
nose to anus with an Ultra-Cal IV Electronic Digital Calliper (Ted
Pella). C/EBPb KO mice were obtained from The Jackson Labora-
tory (STOCK Cebpbtm1Vpo/J, Jackson Laboratory stock no: 006873)
and only used for generating C/EBPb KO MEFs. All animal experi-
ments were performed in compliance with protocols approved by
the Institutional Animal Care and Use Committee.
Feeding experiments
Male mice were caged individually, and daily food consumption
was measured for 7 days. In the subsequent 4 weeks, the mice
received every day 70% of their normal food consumption at 6 p.m.
(caloric restriction).
Rapamycin treatment
Mice were injected i.p. with 8 lg rapamycin per gram body weight
(1.2 mg/ml rapamycin, 0.25% (w/v) PEG, 0.25% (v/v) Tween-20
in H2O) or solvent. Twelve or twenty-four hours after injection,
mice were sacrificed and tissue samples were taken for immunoblot
analyses.
Body composition
The abdominal region from lumbar vertebrae 5 to 6 of anaesthetised
mice was analysed with an Aloka LaTheta Laboratory Computed
Tomograph LCT-100A (Zinsser Analytic). Scans were performed
with a resolution of 1.00 mm with high X-ray voltage and fast speed
settings. Visceral and subcutaneous fat was discriminated with the
supplied software (for visceral fat measurement).
Caloric utilisation
Faeces and food samples were collected and dried in a speed
vacuum drier for 5 h at 60°C and then grinded and pressed into
tablets. Energy content of food and faeces was determined by bomb
calorimetry (IKA-Calorimeter C 5000). Energy efficiency was calcu-
lated by subtracting energy loss in faeces from consumed energy.
Energy expenditure
O2 consumption and CO2 output were measured simultaneously
through indirect calorimetry with an Oxymax Comprehensive Lab
Animal Monitoring System CLAMS open circuit system (Columbus
Instruments). Mice were placed in individual metabolic cages with
free access to water and food. Measurements were performed every
18 min for 48 h starting at 6 p.m. For graphical presentation, the
average of four measurements was taken.
Animal activity measurement
Activity was monitored with the Oxymax CLAMS open circuit
system (Columbus Instruments) over 18 h starting at 10 a.m. Move-
ments were recorded for 18-min intervals for the x-axis and z-axis
and total movements and ambulatory movements counted. For
graphic presentation and analyses, average values for day and night
(6 p.m.–6 a.m.) phases were used.
Blood tests
Mice were anaesthetised with isoflurane, and whole blood was
collected from the suborbital node with heparinised capillaries into
heparin blood collection tubes. Plasma was separated from cells
by centrifugation at 5,000 × g for 10 min at 4°C. Levels of
insulin, adiponectin and leptin were measured by enzyme-linked
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immuno-sorbent assay (ELISA) according to the instructions of the
manufacturer (Biocat). Lipids in serum were determined by
standard clinical laboratory techniques. Free fatty acids (FFA) were
determined by enzymatic conversion to H2O2 followed by a colori-
metric peroxidase assay. Cholesterol, LDL, HDL and triglycerides
were analysed with the Architect System from Abbott. For
measuring LDL and HDL, all non-LDL and non-HDL were removed
prior to analysis, respectively. The procedure for the determination
of triglycerides is described in [42,43]; however, 4-chlorophenol
was used instead of 2-hydroxy-3,5-dichlorobenzene sulphonate.
Glucose tolerance and insulin sensitivity
For the i.p. glucose tolerance test, mice were fasted overnight (16 h)
and injected i.p. with 10 ll of a 20% (w/v) glucose solution per
gram body weight. Blood glucose concentration was measured
with a glucometer (Accu Chek Aviva, Roche). For the i.p. insulin
sensitivity test, mice that had free access to food before, but not
during the experiment, were i.p. injected with 0.5 IU/kg insulin
(0.05 IU/ml insulin in 1× PBS with 0.08% BSA fatty acid-free) and
blood glucose concentration was measured as described before. For
determination of insulin sensitivity in muscle, mice were fasted for
6 h and injected i.v. with 0.75 IU/kg insulin (0.21 IU/ml insulin in
1× PBS) or solvent. Ten minutes after injection, mice were sacrificed
and tissue samples were collected and analysed in an immunoblot
using Akt- and phospho-Akt-specific antibodies (see below).
HOMA2-IR was calculated using the HOMA2 Calculator v2.2.3 from
the Diabetes Trials Unit, University of Oxford (http://www.dtu.ox.
ac.uk/homa).
Immunoblot analyses
For protein extraction, mouse tissue was homogenised in 500 ll
tissue lysis buffer (60 mM Tris pH 6.8; 1% SDS, supplemented with
protease and phosphatase inhibitors) with a glass douncer on ice.
Protein extracts were sonicated and centrifuged for 5 min at
10,000 × g at 4°C, and the fatty layer and cell debris were removed.
For protein extraction from cells, these were washed twice with ice-
cold 1× PBS and lysed in 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, supplemented with protease and phospha-
tase inhibitors followed by sonication. Equal amounts of total protein
were separated by SDS–PAGE, transferred to a PVDF or nitrocellu-
lose membrane and analysed by using the following antibodies:
C/EBPb (C-19), 4E-BP1 (C-19) and a-tubulin (TU-02) from Santa Cruz;
phospho-p70S6K (Thr389) (108D2 or 1A5) and p70S6K (#9202)
phospho-S6 ribosomal protein (Ser235/236) (2F9), S6 ribosomal
protein (54D2), phospho-Akt (Ser473) (D9E) and (Thr308) (L32A4),
Akt (#9272), phospho-4E-BP1 (Thr37/46) (#9459), phospho-eIF4E
(Ser209) (#9741), eIF4E (#9742), 4E-BP2 (#2845), raptor (24C12),
rictor (53A2), acetyl-CoA carboxylase (ACC, #3676), fatty acid
synthase (FAS, #3180) and HSL (34107) from Cell Signaling, b-actin
(AC-40) A3853 from Sigma, Glut4 (#NBP1-49533) and CD36
(#NB400-144) from Novusbio, AOX1 (#10957) from Proteintech and
MCAD (#ab129420) from abcam and the following secondary anti-
bodies: rabbit IgG, HRP-linked antibody from donkey and mouse IgG
HRP-linked antibody from sheep from GE Healthcare. For detection,
the Western lightning Plus-ECL reagent (PerkinElmer) was used. For
re-probing, membranes were incubated in Restore Western Blot
Stripping buffer (Perbio). Quantification of the protein bands was
performed using the FluorChemE Imager (Proteinsimple/Biozym) or
the ImageQuant LAS 4000 Mini Imager (GR Healthcare) and the
supplied software or the ImageJ software [44] in case of films.
Histology and immunofluorescence
Pieces of tissue were fixed with 4% paraformaldehyde for 24 h and
embedded in paraffin. 5-lm-thick sections were stained with
haematoxylin and eosin (H&E) using the Autostainer XL (Leica). For
Sudan III staining, 10-lm cryosections fixed with 4% paraformalde-
hyde were stained for 30 min with Sudan III staining solution (3%
(w/v) Sudan III in 10% ethanol and 90% acetic acid). For immuno-
histofluorescence, paraffin sections were treated with 10 mM citrate
buffer pH 6.0 for 10 min at sub-boiling point for antigen retrieval.
Sections were cooled down to RT and washed three times with 1×
PBS. After blocking for 1 h with blocking buffer (5% (v/v) goat
serum, 1% (w/v) BSA, 0.4% (v/v) Triton X-100 in 1× PBS), sections
were incubated with the primary antibody (rabbit IgG insulin (H-86)
antibody, Santa Cruz) at 4°C over night in a humidified chamber.
After washing with 1× PBS, slides were incubated with Alexa Fluor
488-conjugated secondary antibody (Invitrogen) for 2 h at RT. After
washing with PBS, sections were sealed with cover slips using DAPI
containing mounting medium. All microscopic analyses were done
with the Imager ApoTome Axiovert 200 and Axiovision (Zeiss) soft-
ware.
qRT–PCR analyses
Tissue pieces were homogenised with the Precellys 24 system (Peq-
lab) in the presence of 1 ml QIAzol reagent (QIAGEN), and RNA
was isolated from tissue samples using the RNeasy Lipid Tissue
Mini Kit (QIAGEN). After incubation for 30 min at 37°C with RQ1
RNase-Free DNase (Promega), the RNA was further purified with
the RNeasy Plus Mini Kit (QIAGEN) according to the manufac-
ture’s protocol starting at step 4. For cDNA synthesis, 1 lg RNA was
reverse transcribed with the Transcriptor First Strand cDNA Synthe-
sis Kit (Roche) using Oligo(d)T primers. qRT–PCR was performed
using the LightCycler 480 SYBR Green I Master Mix (Roche). The
following primer pairs were used: b-actin: 50-AGA GGG AAA TCG
TGC GTG AC-30 and 50-CAA TAG TGA TGA CCT GGC CGT-30, GH:
50-CTT CTC GCT GCT GCT CAT C-30 and 50-ATC TTC CAG CTC CTG
CAT CA-30, UCP1: 50-CTG GGC TTA ACG GGT CCT C-30 and 50-CTG
GGC TAG GTA GTG CCA GTG-30, C/EBPa: 50-CAA GAA CAG CAA
CGA GTA CCG-30 and 50-GTC ACT GGT CAA CTC CAG CAC-30,
C/EBPb: 50-CTG CGG GGT TGT TGA TGT-30 and 50-ATG CTC GAA
ACG GAA AAG GT-30, PPARc: 50-GCC CTT TGG TGA CTT TAT GG-
30 and 50-CAG CAG GTT GTC TTG GAT GT-30, GLUT4: 50-CTG TCG
CTG GTT TCT CCA AC-30 and 50-CAG GAG GAC GGC AAA TAG
AA-30, CD36: 50-TGG CCT TAC TTG GGA TTG G-30 and 50-CCA GTG
TAT ATG TAG GCT CAT CCA-30, LPL: 50-GGG CTC TGC CTG AGT
TGT AG-30 and 50-TGG AAC ACT TTG TAG GGC ATC-30, SREBP1c:
50-AAC GTC ACT TCC AGC TAG AC-30 and 50-CCA CTA AGG TGC
CTA CAG AGC-30, FAS: 50-ACA CAG CAA GGT GCT GGA G-30 and
50-GTC CAG GCT GTG GTG ACT CT-30, HSL: 50-CTC CAC ATG CCC
CTC TAC AC-30 and 50-CAG AGC GCA AGC CAC AAG-30, ATGL: 50-
GGA ACC AAA GGA CCT GAT GA-30 and 50-ACT CCA ACA AGC
GGA TGG T-30, AOX: 50-AAG AGT TCA TTC TCA ACA GCC C-30 and
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50-CTT GGA CAG ACT CTG AGC TGC-30, ACC (liver): 50- GGG ACT
TCA TGA ATT TGC TGA TTC TCA GTT-30 and 50-GTC ATT ACC
ATC TTC ATT ACC TCA ATC TC-30, ACC (WAT): 50-TCC ACG AAA
AGA GCT GAC CT-30 and 50-ACT AAG GAT GCT CCC CAC CT -30,
SCD1: 50- CCG GAG ACC CTT AGA TCG A-30 and 50-TAG CCT GTA
AAA GAT TTC TGC AAA CC-30, aP2: 50-GGA TGG AAA GTC GAC
CAC AA-30 and 50-GCT CAT GCC CTT TCA TAA ACT C-30, GLUT2:
50-GCA ACT GGG TCT GCA ATT TT-30 and 50-CCA GCG AAG AGG
AAG AAC AC-30, VLCAD: 50-TTG TCA ACG AGC AGT TCC TG-30
and 50-AGC CTC AAT GCA CCA GCT AT-30, LCAD: 50-GCT GCC CTC
CTC CCG ATG TT-30 and 50-ATG TTT CTC TGC GAT GTT GAT G-30,
MCAD: 50-GGT TTG GCT TTT GGA CAA TG-30 and 50-TGA CGT
GTC CAA TCT ACC ACA-30, SCAD: 50-CCT GCA ACC GAG AAG
AAA TC-30 and 50-CCT GTC CTG TCC CTT GTG TT-30, PGC1a: 50-
GTA AAT CTG CGG GAT GAT GG-30 and 50-GGT GGA AGC AGG
GTC AAA A-30, PRDM16: 50-GAC ATT CCA ATC CCA CCA GA-30
and 50-CAC CTC TGT ATC CGT CAG CA-30, Dio2: 50-CAG TGT GGT
GCA CTG CTC CAA TC-30 and 50-TGA ACC AAA GTT GAC CAC
CAG-30.
Data analyses
Sample size was chosen based on our previous experiments and
published studies in which the same experimental procedures were
used. Animals were randomly assigned for measurements or treat-
ments. Experimental groups were created concerning similarity in
age and body weight. Animals that became sick or died during the
experiment and those with which the experimental performance
was not successful were excluded from analyses. For all data,
normal distribution was assumed and the unpaired, two-tailed
Student’s t-test was used to calculate statistical significance of
results. All graphs show average  standard error of the mean
(s.e.m.). *P < 0.05; **P < 0.01; ***P < 0.005. No blinding of inves-
tigators was done.
Expanded View for this article is available online:
http://embor.embopress.org
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